[{"id":"e04f5494-d279-4e73-86ac-66647b597c64","acronym":"","url":"https://clinicaltrials.gov/study/NCT05757492","created_at":"2023-03-07T18:02:53.388Z","updated_at":"2024-07-02T16:35:18.481Z","phase":"Phase 1/2","brief_title":"Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05757492","lead_sponsor":"Coherus Biosciences, Inc.","biomarkers":" EGFR • PD-L1 • ALK • MET • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK mutation • MET mutation • ROS1 mutation","tags":["EGFR • PD-L1 • ALK • MET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation • MET mutation • ROS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • JS006"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 04/26/2023","start_date":" 04/26/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-02-20"}]